Terms: = Lung cancer AND ABCG2, ABC15, ABCP, BCRP, BCRP1, BMDP, CD338, CDw338, EST157481, GOUT1, MRX, MXR, MXR-1, MXR1, UAQTL1 AND Prognosis
40 results:
1.
Sałagacka-Kubiak A; Zawada D; Saed L; Kordek R; Jeleń A; Balcerczak E
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445716
[TBL] [Abstract] [Full Text] [Related]
2. [Correlation between the mRNA levels of bcrp and LUNX genes and pathological types and stages of patients with non-small cell lung cancer].
Chen D; Han W; Wang P; Ma H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Feb; 40(2):202-207. PubMed ID: 36709941
[TBL] [Abstract] [Full Text] [Related]
3. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ
Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332
[TBL] [Abstract] [Full Text] [Related]
4. Impact of ABCB1, ABCC1, ABCC2, and abcg2 variants in predicting prognosis and clinical outcomes of north Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
Sharma P; Singh N; Sharma S
J Gene Med; 2023 Jan; 25(1):e3460. PubMed ID: 36314103
[TBL] [Abstract] [Full Text] [Related]
5. PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma.
Thirusangu P; Ray U; Sarkar Bhattacharya S; Oien DB; Jin L; Staub J; Kannan N; Molina JR; Shridhar V
Oncogene; 2022 Aug; 41(33):4003-4017. PubMed ID: 35804016
[TBL] [Abstract] [Full Text] [Related]
6. Inhibitors of ABCB1 and abcg2 overcame resistance to topoisomerase inhibitors in small cell lung cancer.
Omori M; Noro R; Seike M; Matsuda K; Hirao M; Fukuizumi A; Takano N; Miyanaga A; Gemma A
Thorac Cancer; 2022 Aug; 13(15):2142-2151. PubMed ID: 35719112
[TBL] [Abstract] [Full Text] [Related]
7. Surface osteosarcoma: Predictors of outcomes.
Lee SJ; Lans J; Cook SD; Chebib I; Schwab JH; Raskin KA; Lozano-Calderón S
J Surg Oncol; 2021 Sep; 124(4):646-654. PubMed ID: 34043244
[TBL] [Abstract] [Full Text] [Related]
8. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma.
Kawachi H; Kunimasa K; Kukita Y; Nakamura H; Honma K; Kawamura T; Inoue T; Tamiya M; Kuhara H; Nishino K; Mizote Y; Akazawa T; Tahara H; Kumagai T
Immunotherapy; 2021 Jul; 13(10):799-806. PubMed ID: 34030451
[TBL] [Abstract] [Full Text] [Related]
9. cancer Stem Cell Markers in Relation to Patient Survival Outcomes: Lessons for Integrative Diagnostics and Next-Generation Anticancer Drug Development.
Dzobo K; Ganz C; Thomford NE; Senthebane DA
OMICS; 2021 Feb; 25(2):81-92. PubMed ID: 33170084
[TBL] [Abstract] [Full Text] [Related]
10. Effect of ABC transporter expression and mutational status on survival rates of cancer patients.
Kadioglu O; Saeed MEM; Munder M; Spuller A; Greten HJ; Efferth T
Biomed Pharmacother; 2020 Nov; 131():110718. PubMed ID: 32932043
[TBL] [Abstract] [Full Text] [Related]
11. The deubiquitylase UCHL3 maintains cancer stem-like properties by stabilizing the aryl hydrocarbon receptor.
Ouyang L; Yan B; Liu Y; Mao C; Wang M; Liu N; Wang Z; Liu S; Shi Y; Chen L; Wang X; Cheng Y; Cao Y; Xiao D; Zhang L; Liu S; Tao Y
Signal Transduct Target Ther; 2020 Jun; 5(1):78. PubMed ID: 32546741
[TBL] [Abstract] [Full Text] [Related]
12. Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis.
Hakozaki T; Okuma Y; Hashimoto K; Hosomi Y
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2555-2564. PubMed ID: 31350622
[TBL] [Abstract] [Full Text] [Related]
13. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell lung cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
Ma G; Zhu J; Liu F; Yang Y
DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
[TBL] [Abstract] [Full Text] [Related]
14. Activation of AhR with nuclear IKKα regulates cancer stem-like properties in the occurrence of radioresistance.
Yan B; Liu S; Shi Y; Liu N; Chen L; Wang X; Xiao D; Liu X; Mao C; Jiang Y; Lai W; Xin X; Tang CE; Luo D; Tan T; Jia J; Liu Y; Yang R; Huang J; Zhou H; Cheng Y; Cao Y; Yu W; Muegge K; Tao Y
Cell Death Dis; 2018 May; 9(5):490. PubMed ID: 29706625
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy; relationship between nestin expression and epithelial to mesenchymal transition related markers.
Ryuge S; Sato Y; Nagashio R; Hiyoshi Y; Katono K; Igawa S; Nakashima H; Shiomi K; Ichinoe M; Murakumo Y; Saegusa M; Satoh Y; Masuda N
PLoS One; 2017; 12(3):e0173886. PubMed ID: 28358810
[TBL] [Abstract] [Full Text] [Related]
16. Depression induces poor prognosis associates with the down-regulation brain derived neurotrophic factor of serum in advanced small cell lung cancer.
Wu Y; Si R; Yang S; Xia S; He Z; Wang L; He Z; Wang Q; Tang H
Oncotarget; 2016 Dec; 7(52):85975-85986. PubMed ID: 27852063
[TBL] [Abstract] [Full Text] [Related]
17. A potentially functional polymorphism in abcg2 predicts clinical outcome of non-small cell lung cancer in a Chinese population.
Sun J; Zhu M; Shen W; Wang C; Dai J; Xu L; Jin G; Hu Z; Ma H; Shen H
Pharmacogenomics J; 2017 Jun; 17(3):280-285. PubMed ID: 26951883
[TBL] [Abstract] [Full Text] [Related]
18. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
Lamba JK; Fridley BL; Ghosh TM; Yu Q; Mehta G; Gupta P
Pharmacogenomics; 2014; 15(12):1565-74. PubMed ID: 25340731
[TBL] [Abstract] [Full Text] [Related]
19. Monitoring microRNAs using a molecular beacon in CD133+/ cd338+ human lung adenocarcinoma-initiating A549 cells.
Yao Q; Sun JG; Ma H; Zhang AM; Lin S; Zhu CH; Zhang T; Chen ZT
Asian Pac J Cancer Prev; 2014; 15(1):161-6. PubMed ID: 24528019
[TBL] [Abstract] [Full Text] [Related]
20. E2F1 drives chemotherapeutic drug resistance via abcg2.
Rosenfeldt MT; Bell LA; Long JS; O'Prey J; Nixon C; Roberts F; Dufès C; Ryan KM
Oncogene; 2014 Aug; 33(32):4164-72. PubMed ID: 24276245
[TBL] [Abstract] [Full Text] [Related]
[Next]
